Marathon of Hope Cancer Centres Network Study for Ontario (MOHCCN-O)

Recruiting

• Conditions: Kidney Cancer; Pancreas Cancer; Leukemia; Solid Tumor; Colorectal Cancer; Breast Cancer; Head and Neck Cancer; Lung Cancer; Prostate Cancer; Melanoma

• Registration Number: NCT05403177
• Lead Sponsor: University Health Network, Toronto

Brief Summary

The Marathon of Hope Cancer Centres Network (MOHCCN) is a national network of cancer centres that pursue collaborative cancer research in precision medicine (an emerging approach for disease treatment and prevention that considers individual variability in DNA, environment and lifestyle) to accelerate the discovery of innovations and improve the health outcomes for cancer patients

Detailed Description

The purpose of this study is to use evolving technologies such as genomics and artificial intelligence to study cancer so that the right treatment can be given to the right patient, at the right time. Approximately 15,000 participants will take part in the greater MOHCCN study across Canada in the first 5 years, and ultimately the goal is to enroll up to 100,000 over next 10 years.

Study Timeline

• Study First Submitted: 2022-05-30
• Study First Submitted QC: 2022-05-30
• Study First Posted: 2022-06-03
• Study Start: 2022-06-23
• Status Verified: 2024-06
• Last Update Submitted: 2024-06-14
• Last Update Posted: 2024-06-18
• Primary Completion: 2026-10
• Study Completion: 2026-10

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 500

Inclusion Criteria

1. Patients with histological and cytological confirmation of blood or solid tumor malignancies.

2. All patients must be able to satisfy the required minimum data elements for the 15k gold standard cohort through:

   • existing data that satisfies the minimal requirements of a gold standard case, AND/OR
   • previously collected and sufficient biospecimens (tumor and/or blood samples) for whole-genome and transcriptome sequencing and immunophenotype characterization, AND/OR
   • new blood collection and/or tumor biopsy

3. Agrees to share anonymized clinical and genomic data.

Read More

Exclusion Criteria

None.

Read More

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Number of patients included in a pan-Canadian cohort with comprehensive clinical and genomic data	5 years	Consolidate and annotate data from patients included in a pan-Canadian cohort

Secondary Outcome Measures

Name	Time	Method
Development of standard practices to create a unique shareable dataset of molecular, imaging, clinical and health outcome information on Canadian cancer cases	5 years	Improve the cancer research paradigm by bringing teams or researchers together and leverage valuable information genomic and clinical data from Canadian cancer cases.
Clinical effectiveness and cost-effectiveness of precision cancer medicine to advance clinical implementation and reimbursement decisions	5 years	Health technology assessment tools will be used to evaluate the real-world value of precision medicine
Development and collection of patient-reported outcomes to enhance patient-centeredness in precision cancer medicine	5 years	Health technology assessment tools will be used to evaluate the real-world value of precision medicine

Trial Locations

Locations (1)

Princess Margaret Cancer Centre; 🇨🇦 Toronto, Ontario, Canada